NLS Pharmaceutics (NLSP.Q) announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Quilience® extended release, the Company’s lead drug…
Pharmaceuticals
Valeo Pharma’s (VPH.C) low molecular weight heparin (LMWH) drug, Redesca and Redesca HP, is now eligible for public reimbursement in seven provinces and territories across Canada, as well as…
Hepion Pharmaceuticals (HEPA.Q) today announced positive topline results from its Phase 2a ‘AMBITION’ NASH clinical trial. Additionally, all primary endpoints of the trial were met. “In order to embark…
CNS Pharmaceuticals (CNSP.Q), the company that licenses the drug candidate Berubicin to WPD Pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation…
Tetra Bio-Pharma (TBP.T) announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as a comparator in…
Bioasis Technologies’ (BTI.V) xB3 platform is designed to deliver therapeutics across the blood brain barrier. BTI’s proprietary tech is relevant to the treatment of brain cancers and neurodegenerative diseases….
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and…
Bioasis Technologies (BTI.V) announced they are entering into a research collaboration with Oxyrane UK. As Equity Guru previously reported, Bioasis is developing the xB³ platform, which aims penetrate the…
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name…
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according…